These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24063059)

  • 21. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
    Lokich J
    Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.
    Chiu GN; Wong MY; Ling LU; Shaikh IM; Tan KB; Chaudhury A; Tan BJ
    Curr Drug Metab; 2009 Oct; 10(8):861-74. PubMed ID: 20214582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle.
    Murray JM
    Math Biosci; 1994 Oct; 123(2):183-213. PubMed ID: 7827419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
    Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity.
    Price LA
    Cancer Treat Rev; 1987 Dec; 14(3-4):215-23. PubMed ID: 3440249
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
    Fung AS; Yu M; Ye QJ; Tannock IF
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):585-95. PubMed ID: 23851981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of simple models of periodic protocols for combined anticancer therapy.
    Dołbniak M; Swierniak A
    Comput Math Methods Med; 2013; 2013():567213. PubMed ID: 23653666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.